Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.…
AstraZeneca buys vaccine startup; FDA issues GLP-1 safety warning
Zura Bio (NASDAQ: ZURA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 40 employees.
The shares were at 0.9305 USD on 20 November 2026, down 78.9% over 52 weeks. Its 52-week range is 0.9192 USD to 7.440 USD: the price is 87.5% below the high and 1.2% above the low.
Its market capitalisation is 89.63M USD.
Zura Bio reports return on equity of -67.6% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 187.65M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. The next earnings report is expected on 18 March 2027.